CONTACT
+91 80 2808 2808
info@biocon.com

Biocon  /  Biocon Enters Prestigious Dow Jones Sustainability Emerging Markets Index

Biocon Ltd has been selected to be in the Dow Jones Sustainability Index (DJSI) for 2021 in the Emerging Markets (EM) category.

Biocon Ltd has been selected to be in the Dow Jones Sustainability Index for 2021 in the Emerging Markets category for its progressive Environmental, Social and Governance (ESG) practices, which underscore its commitment to the larger goal of sustainable development.

Biocon made a formal submission for Corporate Sustainability Assessment for its listing on the DJSI for the first time this year and made it to the DJSI EM Index with a Total Sustainability Score of 45 as against an industry average of 18, achieving a 93rd percentile position.

We are among the Top 15 companies from India and one of the 12 companies from the Pharmaceuticals, Biotechnology & Life Sciences sectors to be featured in the index for 2021. A total of 360 Indian companies were invited to participate in DJSI in 2021.

Last year, for the first time, Biocon was included in the DJSI Index without submission and we got a score of 18. This year Biocon and Biocon Biologics collaborated with PwC and submitted a detailed report to DJSI.

Our Score Card:
  • We have secured Total Sustainability Score of 45, as against an industry average of 18
  • In Governance and Economic Dimension our score is 50, against an industry average of 25.
  • In Environmental Dimension we have scored 43, as against an industry average of 10
  • In Social Dimension we scored 39 as against an industry average of 10
Our Scores based on various parameters:
Our Scores based on various parameters

At Biocon and Biocon Biologics we have made a conscious effort to integrate environmental, social and governance agenda into the core of our business.

Sustainability has been among Biocon’s topmost priorities since inception and both Biocon and Biocon Biologics are committed to provide insights into their ESG performance to their stakeholders.

Our operations have been designed to enable environmental sustainability with a low carbon footprint, complete recycling of wastewater and maximum use of green power. We are committed to diversity and inclusion at the workplace and are consistently endeavoring to create a collaborative and empowering work culture, in pursuit of building businesses that make a meaningful social impact. We have established globally benchmarked standards of governance to build an environment of trust, transparency and accountability.

Read More >>

Our-stories-847
Hope. Now within reach
novel-biologics-biocon-banner
Meeting unmet patient needs
research-innovation-biocon-banner
Research Saves Lives
First to Launch an Interchangeable Biosimilar in U.S.
First to Launch an Interchangeable Biosimilar in U.S.
Biocon Certified as a Great Place to Work® : DEI
Biocon Certified as a Great Place to Work® : DEI
Strategic Alliance with Serum Institute to Impact Global Health
Strategic Alliance with Serum Institute to Impact Global Health
Biocon Biologics to Acquire Viatris Global Biosimilars Assets
Biocon Biologics to Acquire Viatris’ Global Biosimilars Assets in Transformational Deal
Share
Previous Next
Close
Test Caption
Test Description goes like this